Atom | Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33

Funder: National Institutes of Health

Due Dates: June 18, 2025 (New/Renewal/Resubmission/Revision) | August 21, 2025 (AIDS) | October 21, 2025 (New/Renewal/Resubmission/Revision) | December 22, 2025 (AIDS) | Additional cycles through December 2027

Funding Amounts: Up to $400,000 direct costs per year for up to 2 years; minimum 25% non-federal cost match required; ~8 new awards per year

Summary: Supports early-stage translational research to identify and characterize small molecule, biologic, and combination product therapeutic candidates for heart, lung, blood, and sleep (HLBS) disorders.

Key Information: Requires a committed Accelerator Partner and a cost match; clinical trials are not allowed; incomplete applications will not be reviewed.

Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial Not Allowed)

Sign in to see full grant listing